Cancer immunotherapy | The PD-L1 pathway

  Рет қаралды 202,113

Roche

Roche

Күн бұрын

Пікірлер: 28
@braveheart4280
@braveheart4280 2 жыл бұрын
best way to express this topic is in this video... thanks
@roche
@roche 2 жыл бұрын
Thank you for your kinds words. That's so good to hear. We appreciate you taking the time to share it with us! Have a nice day ahead!
@JMSouchak
@JMSouchak Жыл бұрын
Excellent and quick PD-1 explanation! Thank you!
@一梅曾
@一梅曾 2 жыл бұрын
Need more people so spread this video more
@jhonatanpiffer676
@jhonatanpiffer676 3 жыл бұрын
That's a very good explanation! Congratulations
@pharmaNutshell.
@pharmaNutshell. 15 күн бұрын
Thank you❤
@sopaanshukla468
@sopaanshukla468 Жыл бұрын
My mother has PDL1 rating of 20. The Assay used to test PDL1 is DAKO-22c3. Can any one tell me how well the medicine - Pembrolizumab - is effective to damp PDL1 interaction woth T- Cells
@patriciaantunes19
@patriciaantunes19 2 жыл бұрын
How to cite this video?
@Burrdmizzle
@Burrdmizzle Жыл бұрын
You and me both😂
@ahmedibrahim-te4sx
@ahmedibrahim-te4sx 6 жыл бұрын
What can we done to solve the problem of PD overexpression ?
@mikeletterst9882
@mikeletterst9882 6 жыл бұрын
Great question, monoclonal antibodies against PD-1 have been developed that prevent the binding of PD-1 to PD-L1; this block T cell inhibition, thereby restoring the cytotoxic response and promoting apoptosis of tumor cells. Anti-PD1 therapy is used in advanced melanoma and certain types of lung cancer. Unfortunately, the clinical effectiveness of PD-1 immune blockade is still uncertain.
@jwbbccp
@jwbbccp 5 жыл бұрын
Mike Letterst Great answer! Moreover, I believe there is additional concern that PD-1 blockade may significantly increase the risk for autoimmune disease, hence why it is only being used in cases of advanced melanomas and similarly “untreatable” fatal conditions... basically, when the increased risk of lifelong autoimmune disease is outweighed by the higher probability of death.
@khouse1554
@khouse1554 4 жыл бұрын
Jon Wood yea and at the end of the day because of that patients can develop resistance to immunotherapy. Need to figure out ways to indirectly also downregulate PD-L1 on cancer cell to improve this blockade
@rosylindt7255
@rosylindt7255 3 жыл бұрын
@@mikeletterst9882 It is also important to note that patients response depends on other factors such as the tumo microenvironment, the tumor mutation profile and it is also specific to individual patient (this part being the key mystery). This therapy has been used to treat PD1+ tumors but with poor response but other tumors such as melanoma and lung cancer are responding well to these therapies
@taniabelerique2454
@taniabelerique2454 Жыл бұрын
Traduz em português?
@NancyThomas-r8e
@NancyThomas-r8e 2 ай бұрын
Abel Orchard
@KathleenLong-y7g
@KathleenLong-y7g 3 ай бұрын
Daphney Neck
@MonroeWendell-j3m
@MonroeWendell-j3m Ай бұрын
Casper Tunnel
@JohnLee-o3j
@JohnLee-o3j 3 ай бұрын
Bins Meadow
@lucilabascur1862
@lucilabascur1862 8 жыл бұрын
Traducir al español porfavor gracias.
@Hangimin1992
@Hangimin1992 7 жыл бұрын
Lucila Riquelme iii
@GrtvJinr-g2c
@GrtvJinr-g2c 2 ай бұрын
Metz Vista
@RobertoNeizer-x6x
@RobertoNeizer-x6x 2 ай бұрын
Harber Heights
@AliceFryer-x8y
@AliceFryer-x8y 2 ай бұрын
Luettgen Stream
@VincenzoAdebisi-i4o
@VincenzoAdebisi-i4o 2 ай бұрын
Bernier Run
PD-L1/PD-1 pathway: a security checkpoint
3:21
Roche
Рет қаралды 75 М.
So Cute 🥰 who is better?
00:15
dednahype
Рет қаралды 18 МЛН
We Attempted The Impossible 😱
00:54
Topper Guild
Рет қаралды 30 МЛН
Drawn to Science | T-cell bispecific antibodies
3:00
Roche
Рет қаралды 56 М.
Zukunftstag 2024
1:17
Roche
Рет қаралды 935
Lebensqualität trotz Lungenkrebstherapie
1:13
Roche
Рет қаралды 50
Camilla Danckaarts Children's Walk Ambassador trip 2024
3:24
So Cute 🥰 who is better?
00:15
dednahype
Рет қаралды 18 МЛН